TOKYO -- The rapidly advancing field of cancer immunotherapy is pushing Takeda Pharmaceutical and its global competitors to make a series of bold deals in order to position themselves in one of the most promising areas in pharmaceuticals.
One major impetus for spending around 6 trillion yen ($55 billion) to take over Irish peer Shire is that Takeda finds itself playing catchup to the likes of Ono Pharmaceutical, the domestic rival that developed the blockbuster cancer medication Opdivo.
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
to learn how you can update your cookie settings.